A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma.

ABSTRACT: Immune checkpoint inhibitor (ICI) therapy has become a powerful clinical strategy for treating melanoma. The relationship between somatic mutations and the clinical benefits of immunotherapy has been widely recognized. However, the gene-based predictive biomarkers are less stable due to the heterogeneity of cancer at the individual gene level. Recent studies have suggested that the accumulation of gene mutations in biological pathways may activate antitumor immune responses. Herein, a novel pathway mutation signature (PMS) was constructed to predict the survival and efficacy of ICI therapy. In a dataset of melanoma patients treated with anti-CTLA-4, we mapped the mutated genes into the pathways and then identified seven significant mutation pathways associated with survival and immunothera

SUBMITTER: Wang Q 

PROVIDER: S-EPMC10123336 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature